Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -3.39% 14.25 14.00 14.50 14.75 14.25 14.75 255,025 14:38:42
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.1 -4.4 - 35

Futura Medical Share Discussion Threads

Showing 16901 to 16919 of 19275 messages
Chat Pages: Latest  687  686  685  684  683  682  681  680  679  678  677  676  Older
DateSubjectAuthorDiscuss
01/7/2019
13:19
J777J 'I agree and it is actually twice the size of the ED market.' I'm not too surprised by that. Arthritis of the knee, say, not bad enough for an op, or maybe the patient too unfit for surgery, but very debilitating and painful. Lots of potentially very unpleasant side effects, some very serious, from oral NSAIDs. Try morphine or similar instead? again side effects are marked and of course they're addictive. So an effective topical NSAID such as TPR100, with reduced risk of systemic side effects, will be a valuable and welcome addition to the therapeutic armoury.
rrr
01/7/2019
13:11
That was on top of $75 million paid upfront after only a phase 2 study. "Lilly agreed to pay Icos, a biotechnology start-up company that owns the rights to the drug, an up-front fee of $75 million. Analysts said that amount was extremely high for a drug that had not yet entered the final, and most important, phase of clinical trials. In another unusual arrangement, the two companies will share the marketing and sales of the drug in North America and in Europe and split the profits 50-50."
j777j
01/7/2019
11:58
I agree and it is actually twice the size of the ED market. Liberum did not even include it in their last report. Topical Pain Relief Market to Reach $13.27 Bn, Globally, by 2025 Increase in geriatric population, rise in prevalence of arthritis, high demand from athletes, and lesser side effects as compared to conventional oral medicines facilitate the growth in the global topical pain relief industry. Non-opioids segment is likely to be lucrative from 2018 to 2025. Over-the-counter pain relief segment to lead in terms of revenue and growth by 2025. E-commerce segment to register the highest growth rate by 2025. Asia-Pacific to grow the fastest during the forecast period
j777j
01/7/2019
11:20
Don't forget TPR100: TPR100 - Topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism Marketing authorisation application by UK commercialisation partner, Thornton & Ross (a subsidiary of STADA AG) submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in July 2018. Ongoing commercial discussions with several potential distribution partners for other territories. Any further licensing deals are expected to be after UK regulatory approval. TPR100 - Post year end Supporting Thornton & Ross on responses to initial MHRA feedback received in February 2019. hTTps://www.futuramedical.com/content/news/archive19/100419.asp
rrr
01/7/2019
10:57
I meant over the next day or two.
tiananmen
01/7/2019
10:35
I am particularly interested in the 56p level,where a lot of investors bought shares.
j777j
01/7/2019
10:31
44p target next
tiananmen
01/7/2019
09:26
Huge and growing marketplace. Where viagra at launch became the fastest prescription product ever launched. Med2005 works in 5 to 10 mins v up to one hour. Global Erectile Dysfunction Drugs Market Will Reach USD 7.10 Billion by 2024: Zion Market Research According to the report, global erectile dysfunction drugs market was valued at approximately USD 4.82 billion in 2017 and is expected to generate revenue of around USD 7.10 billion by end of 2024, growing at a CAGR of around 5.70% between 2018 and 2024. Inetresting to note how much larger the market is (double the size,) according to independent research is,compared to the Liberum forecast where the see 140p as level if trials are complete success. So that number could turn out to be conservative.
j777j
01/7/2019
09:04
No matter how much medication is applied at some point it will loose its effectiveness.
glavey
01/7/2019
08:42
Interestingly the share price is still 60% below 2016 levels and yet they are within 12 weeks of phase 3 results.
j777j
28/6/2019
20:19
From 7p to 35p in eight months, and now half way to being a ten bagger.
swiftnick
28/6/2019
13:40
TPR100 approval stock will hit £1+ and with positive Phase readout of MED stock will explode to £3+ and its highly likely that results will be positive .. STRONG BUYYYYYYYYYYYYYYYYYYY love it
ih_116147
28/6/2019
12:18
When you factor in the Liberum report's numbers are significantly less than Futura's 2 independent reseach forecasts indicating around $1.4 peak sales. The upside they have, could well turn out to be a low ball number. Why on earth risk taking a pill when you can apply a much faster a safer topical gel? This is disruptive technology. When the Ceo is telling us that as of yesterday they have had huge interest,makes me think he is speaking to long suffering shareholders.
j777j
28/6/2019
11:10
That's a load of potential upside from the current price.
cf456
28/6/2019
09:22
All going well, a great stock to add on the dips, charts v. Good!
ny boy
28/6/2019
08:53
Simon Thompson in the IC certainly sees the potential: "I maintain my view that Futura's share price has the potential to multiply many times over if the £62m market capitalisation company delivers the headline data that potential commercial partners are looking for." hTTps://www.investorschronicle.co.uk/comment/2019/06/20/futura-s-huge-potential-arouses-investor-interest/
cf456
28/6/2019
08:51
I think Fum have a disruptive product that could surprise in how fast it gains acceptance. Remember when Viagra launched it had around $600 million sales in year one! "At the time of its approval, Viagra had the fastest initial sales growth following its launch of any prescription product, reaching 2008 sales of close to $2 billion."
j777j
28/6/2019
07:47
htTP://www.liberum.com/videos/futura-medical
j777j
28/6/2019
07:45
Barder very bullish in latest video interview.There is "huge interest" in the Med gel.
j777j
Chat Pages: Latest  687  686  685  684  683  682  681  680  679  678  677  676  Older
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200924 21:39:49